Standout Papers

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastat... 2020 2026 2022 2024251
  1. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma (2020)
    Sean M. McBride, Eric J. Sherman et al. Journal of Clinical Oncology

Immediate Impact

3 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
1 intermediate paper

Works of Lara Dunn being referenced

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.
2022
A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
2018

Author Peers

Author Last Decade Papers Cites
Lara Dunn 868 436 422 555 87 1.7k
Sze Huey Tan 820 389 319 347 82 1.7k
Wen-Fei Li 887 987 576 649 62 1.9k
Yuan Zhang 603 745 304 444 71 1.4k
Robert E. Wittes 916 175 378 463 42 2.0k
Ethan B. Ludmir 770 96 700 557 189 2.0k
Cheng Xu 877 314 461 339 101 1.7k
A. Hartley 814 702 506 847 67 1.8k
Nicole G. Chau 1224 468 439 758 79 2.2k
Sungjin Kim 585 396 624 546 86 1.8k
Ilaria Girolami 525 100 425 232 76 1.4k

All Works

Loading papers...

Rankless by CCL
2026